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With the expansion of Nuclear Medicine techniques in developing countries, it is essential to 
ensure a quality imaging procedure. In the case of red cell labelling, any factor which 
interferes with the labelling can lead to sub-optimal studies. With regard to the high incidence 
of malaria in sub-Saharan African countries in general and in Cameroon particularly, a high 
percentage of patients referred to Nuclear Medicine departments also have malaria. The 
question arose whether the presence of Plasmodium in erythrocytes or anti-malarial 
medication could affect the labelling of erythrocytes with technetium-99m. 
The aim of this study was to investigate the impact of Plasmodium and anti-malarial 
medication on Tc-99m red cell labelling efficiency with in vitro kits in a population with a 
high prevalence of malaria infection.  
Approval for this study was obtained from ethics committees of both institutions. Three 
groups of 30 patients were enrolled in the study after giving informed consent:  
1. Smear-negative patients in an area where malaria is endemic (control group M-). 
2. Patients with malaria as determined by a positive malaria smear test (group M+). 
3. Patients with malaria and on anti- malaria medication (group Mm). 
From each patient, a 5 ml blood sample was drawn in a heparinised blood collection tube. The 
red blood cells of each sample were labelled in vitro with Tc-99m, using an in vitro red blood 
cell kit. Labelling efficiency of the 3 groups was compared. 
The average labelling efficiency was 98.2% ± 2.3% in malaria-free individuals, 98.6% ± 2.6% 
in patients with malaria but not on treatment, and 98.6% ± 1.1% in patients with proven 
malaria on quinine treatment. Non parametric data analysis using the Kruskal-Wallis ANOVA 
test for the percentage of labelling efficiencies showed a P-value of 0.2117 which was a 
confirmation that there was no significant difference between the labelling efficiencies for the 
three groups. 
Radioactively labelled red blood cells are used in various nuclear medicine studies. Various 
drug therapies, including antibiotics, are known to either inflict direct or indirect damage to 
RBCs or their precursors or to impact influx or efflux of Tc-99m-pertechnetate into or out of 
RBCs, thereby decreasing labelling efficiency to such an extent that poor and inaccurate 
diagnostic information is obtained.  
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The results of this study indicate that malaria parasites and anti-malarial treatment with 
quinine do not affect in vitro erythrocyte labelling with Tc-99m, and should thus not interfere 
with nuclear medicine investigations. 




Met die toenemende gebruik van Kerngeneeskunde in ontwikkelende lande is dit noodsaaklik 
om goeie kwaliteit beeldingsprosedures te verseker. In geval van rooiselmerking kan enige 
faktor wat met die merking inmeng tot sub-optimale studies lei. Weens die hoë insidensie van 
malaria in Afrikalande suid van die Sahara oor die algemeen en spesifiek in Kameroen, het ŉ 
hoë persentasie van pasiënte wat na Kerngeneeskunde verwys word, malaria onder lede. Die 
vraag het ontstaan of die teenwoordigheid van Plasmodium in rooiselle of anti-malaria 
medikasie die merking van rooibloedselle met tegnesium-99m kan beïnvloed. 
Die doel van hierdie studie was om ondersoek in te stel na die impak van Plasmodium en anti-
malaria medikasie op die doeltreffendheid van rooiselmerking met Tc-99m met in vitro 
kitsstelle in ŉ populasie met ŉ hoë voorkoms van malaria infeksie.  
Goedkeuring vir hierdie studie is van die etiese komitees van beide betrokke instansies 
verkry. Drie groepe van 30 pasiënte elk is by die studie betrek nadat hulle ingeligte 
toestemming gegee het:  
1. Smeer-negatiewe pasiënte in ŉ gebied waar malaria endemies is (kontrole groep M-). 
2. Pasiënte met malaria soos bepaal deur ŉ positiewe malaria smeertoets (groep M+). 
3. Pasiënte met malaria en op anti-malaria medikasie (groep Mm). 
ŉ Vyf ml bloedmonster in ŉ gehepariniseerde bloedversamelingsbuis, is van elke pasiënt 
verkry. Die rooibloedselle van elke monster is met behulp van ŉ in vitro rooiselkitsstel met 
Tc-99m gemerk. Merkingsdoeltreffendheid van die 3 groepe is vergelyk. 
Die gemiddelde merkingsdoeltreffendheid was 98.2% ± 2.3% in malaria-vrye individue, 
98.6% ± 2.6% in pasiënte met malaria maar sonder behandeling, en 98.6% ± 1.1% in pasiënte 
bewese malaria en op kinienbehandeling. Nie-parametriese data-analise met die Kruskal-
Wallis ANOVA toets het ŉ P-waarde van 0.2117 gelewer, wat bevestig het dat daar geen 
betekenisvolle verskil tussen die merkingsdoeltreffendhede van die drie groepe was nie.  
Radioaktief gemerkte rooibloedselle word in verskeie Kerngeneeskunde studies gebruik. Dit 
is bekend dat verskeie middels, insluitende antibiotika of direkte of indirekte skade aan 
rooiselle of hul voorlopers veroorsaak, of die in- of uitvloei van Tc-99m in rooiselle 
beïnvloed, en sodoende die merkingsdoeltreffendheid in so ŉ mate verlaag dat swak en 
onakkurate diagnostiese inligting verkry word.  
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Die resultate van hierdie studie toon dat malaria parasiete en anti-malaria behandeling met 
kinien nie die in vitro merking van rooibloedselle met Tc-99m beïnvloed nie, en dus nie met 
Kerngeneeskunde ondersoeke behoort in te meng nie 
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Labelling red blood cells with radionuclides is a common process recognized over the past 50 
years [1]. The chemical structure of technetium allows it to be easily attached to a wide 
number of components including red blood cells. Preparation of Tc-99m labelled red blood 
cells is a well known technique in Nuclear Medicine. This preparation is commonly used for a 
number of investigations, in the diagnosis and follow up of a wide range of diseases [2, 3, 4, 
5, 6]. It is especially useful in cardiovascular Nuclear Medicine.  
Many reports indicate that Tc-99m labelling of red blood cells can be negatively affected by 
patient medication and other factors. This led to research on factors which could affect 
labelling efficiency. For example, Spicer et al incubated antineoplastic agents in vitro with 
whole blood and found that this did not interfere with the labelling efficiency of Tc-99m-RBC 
[7]. 
In recent years, sub-Saharan African countries have included more and more Nuclear 
Medicine departments in their healthcare policies with an increasing number of gamma 
cameras in hospitals. This includes increased use of Nuclear Medicine in tropical countries 
where malaria is endemic [8]. Thus there is an increasing possibility that patients referred to 
Nuclear Medicine also have malaria or could be on anti-malaria medication.  
RBC infected by Plasmodium falciparum have been labelled in vitro by Tc-99m and used for 
experimental work in animals [9]. However this work did not discuss the labelling efficiency 
or the stability of Tc-99m-RBC binding. Currently no literature is available on the influence 
of malaria parasites or anti malarial medication on Tc-99m-RBC binding. 
The current study addresses the question if the presence of Plasmodium falciparum in red 
blood cells and the action of the anti-malarial drug quinine on erythrocytes could affect 
labelling of red blood cells with technetium-99m. 
 





Malaria is caused by Plasmodium parasites, spread to humans through the bites of infected 
Anopheles mosquitoes, which bite mainly between dusk and dawn. Four species are known to 
transmit the infection to humans, i.e. Plasmodium vivax, Plasmodium ovale, Plasmodium 
malariae, and Plasmodium falciparum. Some human cases of malaria have also occurred with 
Plasmodium knowlesi, a South East Asian monkey malaria [8]. 
Following the infective bite, the incubation period in most cases varies from 7 to 30 days. The 
shorter periods are seen most frequently with Plasmodium falciparum. The classic malaria 
attack consists of a cold stage with sensation of cold and shivering, followed by a hot stage 
associated with fever, headaches, vomiting and seizures in young children, and finally a 
sweating stage with a to normal temperature. The severe form affects patient’s blood and 
metabolism, and can include severe anaemia due to haemolysis, haemoglobinuria, and acute 
kidney failure [8]. 
 
Epidemiology: 
The protozoa Plasmodium falciparum is the causative agent of the most virulent form of 
human malaria. More than two billion people are at risk for Plasmodium falciparum malaria 
worldwide [10], and more than 700,000 individuals die annually from this disease, 
predominantly in sub-Saharan Africa [11, 12].  
 
Parasitology: 
The overall biology of the life cycle of Plasmodium falciparum in both mosquitoes and 
mammalian hosts consists alternatively of invasive stages and of stages capable of 
intracellular asexual division. There is also a sexual stage of the life cycle which assists in the 
generation of genetic diversity within the parasite population.  
Infection is initiated when sporozoites from the salivary glands of a female Anopheles 
mosquito are inoculated during a blood meal into the human bloodstream. These organisms 
invade hepatic parenchymal cells within an hour [13]. Once in the liver cells, the parasites 
initiate intracellular asexual multiplication. The products of the liver stage (the extra 
erythrocytic merozoites) are liberated from each parenchymal cell into the bloodstream. Here 
they attach to and invade circulating erythrocytes. Inside the erythrocyte, asexual division 
commences and over a period of 48 hours, the parasites develop through a series of 
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morphological changes from “ring” forms to trophozoites and finally to shizonts containing 
daughter erythrocytic merozoites. These are liberated by red cell lysis and immediately invade 
uninfected erythrocytes, producing a repetitive cycle of invasion and multiplication. The 
concomitant release of pyrogens is then responsible for the periodic “agues” which have long 
been a diagnostic feature of malaria infection and which occur at the time of merozoite 
release. The asexual blood forms are in fact the only forms of the parasite which give rise to 
clinical symptoms. 
A minor proportion of merozoites within erythrocytes can undergo a different pathway of 
development in male and female gametocytes. Once fully mature, the gametocyte may return 
to the mosquito if ingested during a blood meal. Inside the mosquito midgut, male and female 
gametes are liberated from their host erythrocytes and fuse to form a zygote. This develops 
into an ookinete which is able to penetrate the gut wall and form an oocyst. At this point a 
further series of asexual divisions take place giving rise to sporozoites which migrate to insect 
salivary glands and thus complete the life cycle.  
 
Figure 1: Life cycle of the malaria parasite in humans and the mosquito vector [13]. 
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Biochemistry of Plasmodium falciparum: 
The malarial parasite like all organisms acquires nutrients from the environment and converts 
these nutrients to other molecules and/or energy for its survival. For example the parasite 
requires amino acids for the synthesis of its proteins [14]. Haemoglobin is an extremely 
abundant protein in erythrocyte cytoplasm and serves as the major source of amino acids for 
the parasite. 
Plasmodium falciparum export proteins into their host red cell cytoplasm [15].  
During the digestion of haemoglobin, malaria parasites generate free haem upon catabolism of 
host haemoglobin in the erythrocyte. The haem moiety is not metabolized and accumulates in 
the parasite digestive vacuole. In order to minimize oxidative toxicity of the ferric iron, the 
free haem is polymerized into crystalline biomineral beta-haematin commonly referred to as 
haemozoin, also called malaria pigment. The haemozoin crystal becomes visible by 
microscopic examination during the trophozoite and schizont stages through the intra 
erythrocytic developmental cycle and continues to grow in size until the parasites are mature 
enough to egress the erythrocyte [14]. 
 
Pathogenesis: 
It appears that the asexual intra erythrocytic stage of the life cycle of the parasite is 
responsible for the pathology of the disease. Erythrocyte invasion and effects of the parasite 
on the infected cell occur as follows: 
The parasite (merozoite) is introduced in the erythrocyte via an initial attachment to the red 
blood cell, causing violent deformations and reorientation of the parasite. Once reorientation 
has occurred, invasion proceeds immediately. As a result of its entry and growth inside the red 
cell, a number of changes occur including: 
 Degradation of soluble host cell proteins mainly haemoglobin, 
 Changes in erythrocyte size and shape, 
 Alteration in the transport properties of the erythrocyte membrane, 
 Degradation of cytoskeletal components of the host cell, 
 Appearance of parasite specific antigens at the erythrocyte surface. 
Sequestration is mediated by exposed parasite antigens at the cell surface [16].  
Each merozoite after entering the red cell is transformed into a trophozoite which starts with 
successive asexual multiplications by nucleus division. In the end this causes the explosion of 
the cells with concomitant fever, destruction of the infected erythrocyte, liberation of 
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merozoite and invasion of new erythrocytes leading to successive endo erythrocytic cycles of 
Plasmodium falciparum. [13].  
 
Pharmacokinetics and mechanism of action of quinine against Plasmodium falciparum: 
Quinine is an important anti-malarial widely used for treatment of malaria caused by 
Plamodium Falciparum, especially in Sub Saharan Africa. [17, 18]. It is extracted from bark 
of Cinchona officinalis, Cinchoma ledgeriana, Cinchona succirubra or Cincona calisaya 
trees, of the family Rubiaceae. Common names include quinine bark, quina, quinine, kina 
kina, China bark, cinchona bark, yellow cinchona, red cinchona, Peruvian bark. 
Quinine can be administered orally, but also parenterally. It acts as blood schizonticide and 
concentrated in food vacuole of Plasmodium falciparum. After oral administration it is 76 to 
88% bioavailable with a half life of about 18 hours, metabolised in the liver and 20% excreted 
by urine. The antimalarial properties of the compound are thought to be a consequence of 
inhibiting parasite growth within infected erythrocytes.  
Quinine like many other clinically used drugs is thought to act by inhibiting the formation of 
haemozoin in the food vacuole. Quinine inhibits nucleic acid synthesis, protein synthesis, and 
glycolysis in Plasmodium falciparum and can bind with haemozoin in parasitized 
erythrocytes. However, the precise mechanism of the antimalarial activity of quinine is not 
completely understood [19, 20, 21]. 
 
       
Figure 2: Schematic presentation of a RBC infected Figure 3: Quinine molecule [13] 
with malaria parasite, whose digestive vacuole is  
shown, containing mature haemozoin (HZ) crystals.  
(Diagram adapted from Weissbuch [13]. 
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RED BLOOD CELL LABELLING 
 
Red blood cell anatomy: 
In humans, mature red blood cells are flexible biconcave disks that lack a cell nucleus and 
most organelles leaving more space for haemoglobin. Haemoglobin is the largest pigmented 
protein responsible for gas transport [22]. Two point four million new erythrocytes are 
produced per second. They develop in bone marrow and circulate for about 100 to 120 days in 
the body before their components are recycled by macrophages, mainly in the spleen, bone 
marrow and liver. Their diameter is about 7.4 micrometers, the edge thickness 2.6 
micrometers and the central thickness 0.8 micrometers [23]. 
 
Labelled red blood cells in Nuclear Medicine: 
Fisher and his collaborators were the first to report radioactive labelling of erythrocytes with 
Tc-99m. Since their work several authors have conducted different investigations in the same 
field [24]. Steven M. Larson found that kit preparation of Tc-99m red blood cell provides an 
excellent blood pool imaging agent [25].   
The availability of a Tc-99m procedure, using a commercial kit to label at high activity level a 
small volume of autologous blood permitted a suitable and non-invasive technique of 
measuring ventricular ejection fractions and regional abnormalities [26]. In addition, 
technetium emits gamma rays of 140 keV and has a physical half life of 6.02 hours; it has 
ideal properties that make it a radionuclide of choice for gamma camera imaging. The 
technique has even been used in newborn infants for red cell mass measurement [27]. 
An in vitro labelling method was described illustrating the predominant 20 hours blood 
clearance half time resulting in excellent image quality for over 24 hours which is an essential 
property for following intermittent gastrointestinal bleeding or for performing repeat cardiac 
function studies over a time interval of several hours [28]. It appears also to be a very good 
procedure for gated equilibrium blood pool imaging [29]. Bauer et al used in vivo / in vitro 
labelling of red blood cells with Tc-99m successfully in patients who had a radionuclide-
ventriculography and those for localization of occult gastrointestinal bleeding and observed 
no adverse side effects [30].  
Superiority of the in vitro labelling procedure over in vivo labelling for gated equilibrium 
blood pool imaging was demonstrated. Left ventricular function was continuously monitored 
using a radionuclide detector after intravenous injection of Tc-99m labelled red blood cells in 
patients with Parkinson’s disease and postural hypotension. The author found that the study 
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may help to clarify the potential risk of sudden postural changes in such patients, which may 
cause fainting, syncope and increase risk of ischemic coronary and cerebrovascular attacks 
[31]. The feasibility of detailed evaluation of a flow characteristic in soft-tissue vascular 
malformations using Tc-99m labelled red blood cells was illustrated. Delayed liver 
SPECT/CT imaging after administration of Tc-99m red blood cells was found to be useful in 
the identification or exclusion of suspected hepatic haemangioma located near regions with 
high vascular activity [32]. 
There is an extensive list of authors who worked on the red blood cell labelling including 
findings on non-imaging Nuclear Medicine [33].  
 
Red blood cell labelling principle and techniques: 
 
During the erythrocyte labelling with Tc-99m, stannous ions (Sn2+) diffuse into red blood 
cells and bind to the cellular components. This is called the “pre-tinning” of red blood cells. 
Pertechnetate (TcO4
-) freely diffuses back and forth across the cell membrane of the 
erythrocytes. The Sn4+ ion and reduced forms of Tc-99m normally can not cross the cell 
membrane. Technetium reduced by Sn2+ can attach to the β- globulin chain of haemoglobin 
inside the erythrocyte [33, 34, 35]. This principle is applicable to in vitro, in vivo and in 
vivitro erythrocyte labelling procedures.  
 
Different procedures of labelling: 
In his comparative study of three labelling methods, Neumann and collaborators [36] 
concluded that in spite of the slightly higher technical investment involved in the in vitro 
labelling method this technique appears to be preferable for gated cardiac blood pool studies 
in view of the excellent labelling quality even though Creutzig in his letter to the editor 
indicated that the technique causes high radiation exposure to the staff [37]. 
 
a) in vivo red blood cell labelling: 
The method consists of reconstitution of a vial of stannous pyrophosphate kit with sterile 
water for injection or sterile 0.9% normal saline solution. A concentration of 10-20 
micrograms of stannous ion per kilogram of body weight is then injected to the patient [33]. A 
pre-tinning step of the red blood cells is thus done in the body by waiting 30 minutes after 
intravenous administration of the solution to the patient. Freshly eluted sodium pertechnetate 
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is then injected intravenously. Red cell labelling occurs within a few minutes in the 
circulating blood. 
According to Early and Sodee [38], only about 75% of radioactivity is attached to red blood 
cells using the in vivo labelling process which is lower than what it is after in vitro labelling. 
The remainder will enter the extravascular space. This becomes a disadvantage in evaluation 
of gastrointestinal bleeding as sodium pertechnetate present in the blood will be secreted by 
the parietal cells of the stomach, causing false positive scans. But about 90% of the injected 
dose remained in the blood pool 2 hours after in vivo red cell labelling of rats and the findings 
suggested that red blood cells labelled in vivo with technetium may be as useful as those 
labelled in vitro for serial ejection-fraction studies and large vessel imaging [39].  
 
b) In vivitro red blood cell labelling: 
This is combination of both in vivo and in vitro methods where red blood cells are “pre-
tinned” in vivo and labelled in vitro, with aim to remove unbound Tc-99m before injection. 
The radioactivity is measured in the method and thus the labelling efficiency can be 
calculated.  
As described by Sampson [40], after a reconstitution of stannous agent with 0.9% sterile 
normal saline solution, 0.03ml/kg of stannous ion is intravenously injected. Fifteen to 30 
minutes after the injection, 10 ml heparinised in vivo tinned blood sample is collected. Sterile 
normal saline 0.9% is then added to the blood sample followed by centrifugation at 500G 
during 5 minutes (washing step). The plasma is then removed and the washing step repeated 
to ensure removal of any extra-cellular stannous ions before adding the required amount of 
TcO4
- to the cells. A 5 minute incubation time follows after which another washing step is 







Where  ARbc = Activity of red blood cells 
AS = Activity of supernatant 
 
Accurate results can be obtained with the in vivitro red blood cell labelling methods [40]. It 
could even produce labelling efficiencies as high as 95% [38]. 
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c) In vitro red blood cell labelling: 
The advantage of in vitro RBC labelling techniques is that extracellular tin can be removed 
before pertechnetate is added to the cells.  
The clinical results of a new Tc-99m red blood cell labelling procedure avoiding cell 
centrifugation were performed. One ml of heparinized blood samples were incubated with kit 
containing stannous ion. By titration studies, ideal quantities of sodium hypochlorite for 
oxidation of extra cellular tin and of EDTA as stabilizer were used. Labelling efficiency 
remained high for two hours after injection. In addition the biological half life of labelled cells 
following the new procedure was 11 to 12 hours, rendering it suitable for serial determination 
radionuclide cardiography [41]. Superiority of the in vitro labelling procedure over in vivo 
labelling for gated equilibrium blood pool imaging was demonstrated using the Ultratag® 
RBC kit, which uses ACD-A and not EDTA [29]. 
This method usually requires the use of a lyophilized or frozen kit containing stannous ions. A 
red blood cell in vitro kit typically contains 50 µg stannous chloride dihydrate (SnCl2.2H2O), 
3.7 mg sodium citrate, 5.5 mg dextrose and 2.0 mg sodium chloride.  
One to two millilitres of heparinized blood are added to the kit. Five minutes incubation on a 
rotator mixer follows to let the stannous ions to enter the red blood cells and bind to the 
cellular components. After that sodium hypochlorite (NaOCl), an oxidizing agent, is added 
[42]. As NaOCl is unable to cross the red cell membrane, it will only oxidize the extra-
cellular Sn2+ to Sn4+. This is done to remove the excess tin in the extra-cellular medium. A 
citric acid/sodium citrate mixture (ACD-A) is added to sequester any residual extra-cellular 
stannous ions. The TcO4
- recommended dose to add to the kit is 370-3700 MBq with an 
incubation time of 20 minutes. The activity of TcO4
- to add to the red blood cells will depend 
on the clinical application. As described in the package insert of the commercially available 
Ultratag® kit, Tc-99m labelled red blood cells should be injected to the patient at this stage 
[43]. With the method described by Le Roux [44] and Lackay [45] which is the same method 
used at Tygerberg Hospital, the vial is centrifuged after labelling and plasma removed from 
the packed red blood cells. Any unbound Tc-99m will be removed with the plasma. The 
labelling efficiency is determined after measurement of the activity of the supernatant as well 
as the activity in the red cell pellet. The percentage of Tc-99m incorporated by the red blood 
cells, which is also called labelling efficiency (%LE), is calculated using the formula 
described above for in vivitro labelling. The red cell pellet is resuspended with sterile normal 
saline (0.9%) solution prior to injection. 
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The indication for the referral of the patient will help to decide about the methods of choice. 
In vivo red cell labelling is convenient as it avoids the direct handling of blood which can be a 
source of infectious contaminations. It consumes less time than the in vitro method. 
Unfortunately the in vivo method generally renders lower labelling efficiencies, which limits 
the usefulness of the method for many applications [36]. For example it is imperative to 
ensure a high labelling efficiency with quantitative applications such as blood volume studies. 
Furthermore in the detection of haemoptysis, poor labelling efficiency will lead to uptake of 
unbound radioactivity in the stomach, which in turn could result in false positive studies. The 
in vitro labelling method would be the method of choice for the above case.  
 
Drugs and disease states affecting red blood cell labelling efficiency: 
There is considerable evidence that the biodistribution or kinetics of radiopharmaceuticals 
may be altered during a disease state as well as due to drug consumption, even when they are 
used as vegetable extracts [46, 47, 48, 49 50]. Radiolabelling red blood cells with Tc-99m can 
be altered by interaction of synthetic and natural drugs [51, 52, 53, 54, 55, 56, 57], in some 
cases resulting in poor diagnostic information [58]. 
Drug interaction as cause of sub-optimal percentage of labelling was suspected with 
nifedipine in combination with other drugs [59], and medication such as doxorubicin cause 
abnormal cardiac distribution [60]. The same decreased effect was found with prazosin as 
well as digoxin [61]. 
To summarise poor labelling efficiency’s causes, Sampson [1] presented a list including: 
- Heparin anti-coagulant rather than acid-citrate dextrose solution A. 
- Oxidation of Tc-99m with exposure to air 
- Inadequate administration of stannous ion 
- Prior administration of intravenous contrast media 
- Patients with sickle cell anaemia  
- Incubation with anti-RhD serum 
- Anti-hypertensive therapy 
- Formation of red blood cell antibodies 
- Interference of drugs such as nifedipine, verapamil. 
Gleue et al [62] incriminated antibiotics (gentamycin) and anti-inflammatory agents. 
 
More detailed studies attempting to clarify the mechanism of interaction with red cell 
labelling were done by a Brazilian group of researchers. Morphological changes of 
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erythrocytes including membrane alteration did not always imply or correlate interference on 
the labelling of blood constituents with Tc-99m. Moreno and co-workers [63] incubated blood 
from Wistar rats in vitro with Nectandra membranacea extract at different concentrations. 
They added successively SnCl2 and sodium pertechnetate. A morphometry study was 
simultaneously conducted by using a drop of each sample for smear tests on glass slides for 
microscopic evaluation with comparison to control blood (blood plus 0.9% saline, SnCl2 and 
sodium pertechnetate). Qualitative analysis of the shape of RBC in samples incubated with 
Nectandra membranacea has shown important qualitative morphological alteration mainly in 
samples treated with highest concentrations, with P-value smaller than 0.05. The radioactivity 
in each sample was determined in a sodium iodide well counter and the percentage of 
administered radioactivity was calculated. The result showed no significant difference of 
values of treated samples with different concentrations of extract and control samples 
(P>0.05).  
Similar results were found from work with Sechium edule [64] where in addition to 
morphological and radiolabelling investigation, electrophoretic mobility of plasmid from 
Wistar rats was studied. In spite of demonstration of microscopic morphological alterations 
and proof of damaging plasmid DNA by electrophoresis, Sechium edule extract was not 
capable of modifying the pattern of radiolabelling of blood elements with Tc-99m. The 
authors suggested that these extracts have anti oxidant compounds which could probably be 
responsible of alteration of the morphology of red blood cells without altering the 
radiolabelling of blood elements [65]. 
 
Another animal model study on female Sprague Dawley rats documented the effect of Bacopa 
monnieri (L) extract on the labelling of blood elements with Tc-99m and on morphology of 
red blood cells [66]. In this case, there was alteration of the morphology with a significant 
decrease of percentage of blood cell labelling. The authors suggested that the effect of Bacopa 
monnieri (L) could be explained by an inhibition of stannous and pertechnetate ions or 
oxidation of the stannous ion or by damages induced in the plasma membrane. 
A report of an in vitro animal model study on influence of biflorin, a potent o-quinone 
antimicrobial product, was documented [67]. From four Wistar rat blood samples incubated at 
different concentrations of biflorin with SnCl2 and sodium pertechnetate, the distribution of 
radioactivity in soluble and in soluble fractions of RBC was recorded. The result indicate an 
extreme decrease (P<0.001) in radioactivity fixation in the insoluble fraction of red blood 
cells only when 0.25mg of bioflorin is added to 0.5ml of blood sample as well as when 
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0.125mg of bioflorin in 0.5ml of blood. However, this work done in animal models differs 
from the situation in patients regarding the volume of blood used, and the actual 
radiolabelling method. The number of animals used per experiment is also very small. It is not 
clear how these experiments would translate into the clinical situation in diagnostic Nuclear 
Medicine. 
 
A more optimal study in humans was done by Lackay [45] where the labelling of erythrocytes 
with Tc-99m was evaluated in patients who were treated with a cocktail of anti-tuberculosis 
drugs. Medicines used in the study included a combination of rifampicin, isoniazid 
pyrazinamide and ethambutol in the first phase of tuberculosis treatment, followed by a four 
months continuation phase of treatment with rifampicin and isoniazid only. Labelling 
efficiency in each treatment phase was compared with each patient’s baseline RBC labelling 
before treatment. No statistically significant difference was found between the baseline 
studies and the labelling done during the two phases of treatment. 
 
Thus from a review of the literature regarding the influence of medication and plant extracts 
on red blood cell labelling the following emerges: 
1. From case studies and small series of observations in patients, it appears that many 
drugs can interfere with RBC labelling with Tc-99m. 
2. Experimental work has been done on the effect of several plant extracts in rats, but it is 
not clear how this would relate to the situation of patients in nuclear medicine. 
3. Very few detailed studies have been done in humans. 
 
With a very high prevalence of malaria in Cameroon and in other Sub-Saharan African 
countries and the fact that the area is endemic for the disease [11, 12, 18], there is potential 
that patients referred for Nuclear Medicine investigations with radiolabelled red blood cells, 
may be infected with malaria and/or on anti malarial therapy. In view of a rich documentation 
on adverse effects due to both disease states and drug interactions on red blood cell labelling, 
the question arises if malaria or quinine would affect the labelling efficiency. However no 
published work could be found with respect to the possible influence of Plasmodium 
falciparum and antimalarial drugs on red cell labelling with technetium-99m.  
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Problem statement 
With the expansion of Nuclear Medicine facilities in developing countries, it is essential to 
secure a high quality imaging procedure. This includes ensuring that any 
radiopharmaceuticals prepared for the patients are safe and effective. In the case of red cell 
labelling, any factor which interferes with the labelling can lead to sub-optimal studies. With 
regard to the high incidence of the malaria in sub-Saharan African countries in general and in 
Cameroon particularly, a high percentage of patients referred to Nuclear Medicine 
departments also have malaria. The question to be answered is whether the presence of 





AIM OF THE INVESTIGATION 
 
The aim of this study is to: 
- determine whether the presence of Plasmodium falciparum in red blood cells and  
- the action of the anti-malarial drug quinine on erythrocytes  
could affect labelling of red blood cells with technetium-99m. 




MATERIALS AND METHODS 
 
This study was approved by the Stellenbosch University Health Research Ethics Committee 
(No: N11/01/022) and Cameroon National Ethics Committee (No: 163/CNE/SE/2010) as well 
as the authorisation of the General Manager of Yaoundé General Hospital. 
The participants gave a written informed consent before being enrolled into the study. The 
patient information sheet was available in English and French.  
 
Study population: 
A prospective study was conducted at the Yaoundé General Hospital (YGH) Nuclear 
Medicine Department, Haematology unit and blood bank unit, and hospitalisation units in 
Cameroon. 
The blood samples used were collected with convenience sampling from day to day patients 
in consultation at YGH and at the “clinique mere et enfant” in Yaoundé, and from 
hospitalised patients in both centres. 
 
Inclusion criteria: 
- Consenting males and females aged between 18 and 60 years 
- Patients free from HIV  
- Patients free from sickle cell disease 
- No chemotherapy and/ or radiotherapy during the last 6 months 
 
Exclusion criteria: 
- On request of the patient 
- Patients on drugs known to interact with red blood cell labelling 
- Patients with psychiatric illness 
- Patients with chronic diseases 
- Critically ill patients 
 
Blood samples were obtained from 3 groups of patients in Yaoundé: 
- Smear-negative patients in an area where malaria is endemic (Yaoundé),serving as a 
control group or Group M- 
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- Patients with malaria as determined by a positive malaria smear test (Group M+) 
- Patients with malaria and on anti- malaria medication (quinine) (Group Mm). 
 
Laboratory records of patients enrolled in the study were reviewed. A total of 105 blood 
samples were collected between March 2011 and June 2011. Nine samples were excluded 
because the patients were HIV positive, 6 were excluded due to haemolysis of the samples.  
The investigation was performed on venous blood samples drawn into 5ml heparin coated 
tubes. 
 
Laboratory blood testing: 
A drop of each sample was used for a rapid HIV test and for preparation of the thick smear for 
malaria parasites. 
Malaria diagnosis: 
The diagnosis of malaria was performed by microscopic examination of blood films stained 
with Giemsa. The thick blood slides were examined by an experienced microscopist to 
determine presence or absence of Plasmodium falciparum.  
Anti Malarial treatment: 
A loading dose of Quinine dihydrochloride 20mg/kg by infusion over 4 hours in 5% dextrose 
was given followed by a maintenance dose: 8 hours after the start of the loading dose, 10 
mg/kg quinine dihydrochloride infused over 4 to 6 hours and repeated every 8 hours until the 
patient could take oral quinine. After that, 2 tablets of quinine 300mg each were swallowed 
every 8 hours with food for 7 days.  
 
Labelling Red Blood Cells: 
 
Protocol: 
The Brookhaven in vitro red blood cell labelling with Tc-99m method as described by Lackay 
[45] was used, with the following steps: 
1. 2 ml of blood were withdrawn from each heparin coated tube and added to an in vitro 
red blood cell kit. 
2. The RBC kit was incubated for 5 min on an automatic rotator. 
3. After incubation, 0.6 ml of a 0.1% sodium hypochlorite solution was added to the 
mixture. 
4. 1 ml Acid citrate dextrose solution A (ACD-A) was added to the vial. 
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5. Tc-99m pertechnetate (600 – 800 MBq) from generator eluate not older than 2 hours 
was added to the vial. 
6. The kits were incubated for 15 min at room temperature and mixed carefully at 
approximately 5 min intervals. 
7. Labelling efficiency (LE) was determined within 5 minutes after completion of 
incubation, after centrifugation of the vial for 5 min at 2000 revolutions per minute, 
removing the supernatant from the red blood cells and measuring the activity of red 
blood cells and supernatant in a dose calibrator. 
 
Measurement: 
The radioactivity of both the packed red blood cells and the supernatant were measured in a 








Analysis of data: 
MS Excel was used to capture the data and non parametric data analysis was performed using 
Statistica software. Data was examined for significant departures from normality using a 
Shapiro-Wilks test. As the data are not distributed normally, the Kruskal-Wallis ANOVA test 
was used. The primary objective was to determine whether there is a significant difference 
between the labeling efficiency of the following groups: 
• Control group 
• Malaria group without anti-malarial medication 
• Malaria group with anti-malarial medication (quinine). 
 
 




In this chapter, the results of the radiolabelling of blood samples includes those from 
individuals without malaria or control group (Group M-), those from patients with malaria 
(Group M+), as well as those from patients with malaria and on quinine therapy (Group Mm).  
A total of 90 individuals were enrolled in the study, both sex included. Thirty blood samples 
were without malaria, 30 others with malaria as determined by positive malaria smear test and 
30 samples from patients with malaria and on quinine medication. All the blood samples were 
from individuals of the same geographic location. Each sample was labelled and their 
percentage labelling efficiency documented. 
Full details of all patient blood samples including age, sex and percentage labelling efficiency 
are provided in table 1, table 2 and table 3 below. 
 









1 M 45 93.81  16 M 24 99.32 
2 F 22 98.49  17 M 39 98.67 
3 M 23 97.97  18 M 23 99.16 
4 F 30 94.93  19 F 53 99.19 
5 F 30 99.40  20 F 23 98.94 
6 F 35 97.82  21 M 28 97.89 
7 M 22 94.58  22 M 36 99.81 
8 F 18 88.71  23 F 34 97.72 
9 M 26 98.69  24 F 40 99.50 
10 F 18 98.63  25 F 24 99.81 
11 M 57 99.22  26 M 25 98.99 
12 M 42 99.37  27 F 42 99.48 
13 F 51 99.46  28 M 51 99.72 
14 F 18 99.70  29 M 41 98.52 
15 F 18 99.65  30 F 42 98.70 
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1 M 25 99.48  16 F 20 98.93 
2 F 54 99.84  17 M 22 99.20 
3 M 27 85.80  18 M 28 99.15 
4 F 20 96.99  19 F 25 99.07 
5 F 22 99.64  20 F 30 98.32 
6 M 25 99.70  21 M 25 98.21 
7 F 20 99.85  22 F 55 99.48 
8 M 28 98.99  23 F 30 99.62 
9 M 28 94.85  24 M 19 99.01 
10 M 25 99.62  25 M 41 98.52 
11 M 27 99.15  26 M 42 99.48 
12 F 30 99.50  27 F 51 99.72 
13 M 24 99.32  28 F 32 99.53 
14 F 38 98.41  29 F 28 99.11 
15 M 31 99.88  30 F 30 99.00 
 
 










1 F 36 98.80  16 F 44 99.49 
2 M 29 99.44  17 M 18 98.33 
3 M 40 97.90  18 M 25 98.99 
4 F 57 97.10  19 F 25 99.10 
5 F 29 94.53  20 M 26 99.77 
6 F 38 99.92  21 F 24 99.44 
7 F 30 97.95  22 F 25 99.12 
8 M 20 98.28  23 M 32 97.74 
9 M 41 99.14  24 M 25 99.48 
10 M 37 96.64  25 M 38 99.17 
11 M 20 99.15  26 F 27 98.11 
12 F 40 99.50  27 F 23 97.24 
13 M 24 98.48  28 M 22 98.90 
14 F 29 98.84  29 F 26 99.70 
15 F 20 99.49  30 F 28 99.00 
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A summary of labelling efficiencies for patient samples with descriptive statistic analysis 
from each group as well as that from all three groups are provided in table 4 below.  
The more complete tables with descriptive statistic analysis are provided in the addendum 
(table A3, table A4, table A5 and table A6). 
 
Table 4: Descriptive statistics for the variable % labelling efficiency (%RBC) for the 
three groups 
Group Valid N Mean Std. Dev. 
Control (M-) 30 98.19500 2.346495 
M+ 30 98.57900 2.610795 
Mm 30 98.62467 1.135781 
All groups combined 90 98.46622 2.114949 
 
Statistical unweighted means analysis per group (see Addendum table A1) showed that there 
was no significant difference in the mean ages of the 3 study groups. Individuals without 
malaria included in the study had a mean age of 32. 7 years. The mean age of the patients with 
malaria was 30.1 years and the group of patients having malaria and on quinine therapy had a 
mean age of 29.9 years. 
 
The control group M- and the malaria therapy group Mm both had samples from 14 males and 
16 females, while the group of patients with malaria but not on treatment (M+) consisted of 
15 males and 15 females. Thus the sex of patients did not influence results (See analysis in 
table A2 addendum). 
 
Two dimensional histograms of labelling efficiencies for each group as well as for all groups 
together were plotted and are represented in figure 4, 5, 6 and 7 below. All the histograms 
present a unique sharp peak. The shape obtained has a non Gaussian distribution of data. 
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Figure 4:  Histogram of percentage of labelling efficiencies in control group M- 
 
Histogram: LE M-
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Figure 5:  Histogram of percentage of labelling efficiencies in group M+ 
Histogram: LE M+
80 82 84 86 88 90 92 94 96 98 100
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Figure 6:  Histogram of percentage of labelling efficiencies in group (Mm) 
Histogram: LE Mm
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Figure 7:  Histogram of percentage of labelling efficiencies in all groups 
Histogram of  all results (all groups combined)
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A non parametric data analysis using the Kruskal-Wallis ANOVA by Ranks test of the 
percentage of labelling efficiencies in all groups was performed. A P-value of 0.2117 was 
obtained as shown in table 5. This confirms that there is no significant difference between 
percentages of labelling efficiencies for the 3 groups. 
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Table 5:  Non parametric data analysis: 
Kruskal-Wallis ANOVA by Ranks; %RBC  
Independent (grouping) variable: GROUP (C/M+/Mm) 
Kruskal-Wallis test: H (2, N= 90) =3.104885 p =0.2117 
Depend.: 
%RBC 
Code Valid N Sum of Ranks Mean   
Control 102 30 1278.500 42.61667 
M+ 101 30 1570.000 52.33333 





The box plot in figure 8 illustrates the similarity of the results from the three experimental 
groups, with means that are very close to each other and overlapping standard errors. 
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CHAPTER FIVE 




Nuclear Medicine studies using red blood cells labelled with Tc-99m are often used as it is an 
excellent tool for many diagnoses, including blood pool imaging and left ventricle ejection 
fraction investigations. Patients enrolled for such studies have concomitant diseases and are 
often on medication.  
 
This study investigated the possible influence of malaria parasites and quinine on in vitro 
labelling of red blood cells. The mean labelling efficiency in our study was 98.2 ± 2.3% for 
the control group, 98.5 ± 2.6% in blood samples infested with malaria parasites, and 98.6 ± 
1.1% in patients with malaria treated with quinine. Similar labelling efficiencies were 
documented by Spicer [7] with a mean LE of 97.8% for a control group and 98.8% for blood 
incubated with antineoplastic drugs. Both studies used the in vitro labelling technique. 
The overall values of LE in all groups in the current study shows a great variability which was 
not sex or age related. The value of labelling efficiencies in the current study ranged between 
85.8% and 99.9%. This broad range of values is not unexpected, and similar to the values 
documented by Lackay using the same labelling technique in a normal volunteer group, with 
values between 86.2% and 99.7% [45]. Although there is no prescribed or pharmacopoeial 
minimum value for red cell labelling efficiency, the producer of the UltraTag® kit states that 
95% should usually be achieved [43], and 90% or more is usually regarded as acceptable for 
clinical studies [45]. In the present study as well as Lackay’s study mentioned above, LE 
exceeded 95% for the majority of samples. In both control group and malaria positive group 
without medication, very few cases had unsatisfactory LE of lower than the typical value of 
95%, with only one case for each group showing a very low LE between 85% and 90%. 
 
The method of labelling and ingredients of the labelling kit, could affect the binding of Tc-
99m in red blood cells. The in vitro method used in this study is documented as giving highest 
percentage of labelling, performing better than in vivo or in vivitro methods [29]. This is well 
shown in the current study with a high mean of labelling efficiencies of all groups combined 
(98.5%). According to Spicer, many of the drugs reported to interfere with other RBC 
labelling techniques, have not been found to interfere with the UltraTag® RBC method [7, 
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62]. It is probable that the in vitro method using sodium hypochlorite after pretinning of the 
cells provides high labelling efficiencies due to the large quantity of stannous ion that allows 
for maximum cell tinning, and the oxidation of extracellular tin by the presence of sodium 
hypochlorite. 
 
A few diseases are reported to affect labelling of red blood cells with Tc-99m, including 
chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma, systemic lupus erythematous, and 
sickle cell anaemia as causes of suboptimal labelling efficiency [68]. However there is usually 
no explanation of the mechanism causing the low labelling efficiencies in these diseases. 
From the pathophysiological mechanism occurring in malaria, haemoglobin is the site of 
action of the parasite inside red blood cells [13, 14]. Haemoglobin is also the site where 
technetium is bound in the erythrocyte [69]. We therefore postulated that there could be 
interference when these two mechanisms occurred at the same time. The current study 
however could not prove a significant difference in labelling efficiencies when erythrocytes 
are labelled with Tc-99m in presence of Plasmodium falciparum (group M+ LE= 98.6%) or in 
absence of the disease (LE control group 98.2 %).  
 
There are many reports of drugs interfering with red cell labelling, but the mechanism of 
interference is not often detailed. The possible explanations of effects of drugs on the 
labelling of blood elements with Tc-99m include a direct inhibition (chelating action) of 
stannous and pertechnetate ions, damage induced in the plasma membrane, competition of the 
ions for the same binding sites, possible generation of reactive oxygen species that could 
oxidize the stannous ion and/or direct oxidation of the stannous ion [70]. Lee et al in 1983 
reported interference of RBC labelling with prazosin and digoxin, and thought that the 
reaction was associated with the fact that digoxin affects red cell membrane transport by 
inhibition of the Na+/K+-ATP-ase dependent pump [71]. According to Tatum et al [72] 
patients who had previously received iodinated contrast media produced a suboptimal red cell 
labelling efficiency. It was found that the mean labelling efficiency in those patients was 30% 
as opposed to 90% in patients who had not received the contrast media. It was then thought 
that the poor labelling efficiency could be due to an alteration in the redox potential of the 
stannous ion and therefore affect its role as reducer of technetium [40]. 
We postulated that quinine might affect red cell labelling with Tc-99m, as its site of action 
against Plasmodium falciparum is in the erythrocyte [13] where Tc-99m is bound to the 
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haemoglobin molecule. However, we could not demonstrate a significant effect, with the 
group Mm having a mean LE of 98.6% compared to 98.2% in the control group. 
 
The literature available on drugs affecting LE varies from simple case reports, laboratory in 
vitro studies, and animal experiments, to experimental work in humans. 
Many drug interferences are known from case reports, including a list summarised by Adalet 
[68]. The list includes drugs like penicillin, doxorubicin, cardiac drugs like prazosin, 
propranolol, hydralazine, methyldopa. Heparinized catheters and quinidine among others 
were also documented to give poor quality red cell labelling [68, 73]. Hambye and coworkers 
did an extensive review of large number of patients’ gated blood pool images after in vivo 
RBC labelling. They found that intravenous heparin and chemotherapy significantly affected 
RBC labelling and image quality [74].  
From case reports, it is usually not possible to gain much information on mechanisms of 
interference. The case reports are however very valuable as they can alert nuclear physicians 
to potential problems.  
 
Many authors focus their work on laboratory in vitro studies mostly performed on animals or 
blood from animals [51, 54, 75]. Abreu and coworkers incubated rat blood samples in vitro 
with guava extract and found that the extract may have antioxidant action and alter the 
membrane structure involved in ion transport in the cells, thus decreasing the labelling of 
blood cells with Tc-99m [76]. Similar laboratory in vitro findings with rat blood incubated in 
presence of Fucus vesiculosus extract used in popular medicine suggested a decrease Tc-99m 
RBC labelling, due to products present in this natural product solution which may complex 
with stannous ions and pertechnetate and have direct or an indirect effect on their intracellular 
concentration or which may modify the plasma membrane and alter their transport into cells 
[77]. Braga and coworkers in 2000 incubated rat blood with extracts of Thuta occidentalis, 
Peumus boldus and Nicotiana tabacum to monitor their effect on Tc-99m labelled RBC. 
Using an in vitro technique, they found that some medicinal plants can affect the 
radiolabelling of RBC with Tc-99m [53]. Another animal experiment from Diré in 2006 
suggested that Sechium edule extract is capable of maintaining the efficiency of labelling of 
blood elements with Tc-99m in diabetic status, although diabetes as such alters the 
radiolabelling of blood constituents by the generation of active metabolites with oxidant 
properties which may alter the function and the structures of proteins [78]. Such laboratory 
studies in animal models could be worthwhile to help to understand the drug interaction in 
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nuclear medicine procedures, avoiding obtaining poor quality images and therefore the 
necessity to repeat the examination increasing the radiation dose to the patient, or even 
misdiagnosis [77]. These studies do however have some limitations. In most cases blood 
samples were incubated in vitro with drugs or plant extracts [76, 53, 51, 54]. This means that 
the influence of metabolites was not studied. In addition, the relevance of the quantities of 
drugs or plant extracts incubated with blood to the clinical situation is not always clear. 
Very limited literature is available describing experimental studies of drug effects on red cell 
labelling in humans as it is not acceptable to administer either medicines or radionuclides to 
human subjects purely for experimental studies. Yet human studies would provide the most 
realistic representation of what can occur in the Nuclear Medicine clinic. Obtaining blood 
samples from patients would to some extent overcome problems, but would also introduce the 
difficulty of controlling other factors such as dose regimen of the medication, the effects of 
concomitant medication, and possible effects of the actual diseases of the patients, to name 
but a few. 
Pauwels et al observed poor RBC labelling on gated blood pool studies of patients who had 
received adriamycin (doxorubicin) a few hours before. They followed this up with in vitro 
labelling experiments, incubating blood samples with adriamycin, that showed varying 
labelling efficiencies, depending on the concentration of adriamycin and incubation time [79]. 
Gerson and coworkers studied the influence of anticoagulants used during blood sample 
collection for in vitro RBC labelling in a group of volunteers and found that EDTA adversely 
affected labelling efficiency. The same authors did an investigation on a modified 
Brookhaven method for in vitro red cell labelling, adding an initial centrifugation step, in a 
series of 50 patients including 12 who were treated with doxorubicin. This technique was not 
influenced by doxorubicin [80]. Spicer [7] investigated the ability of Ultratag RBC kit to label 
RBCs with pertechnetate in presence of various antineoplastic drugs including doxorubicin, 5-
fluorouracil, cyclophosphamide, vincristine and cisplatin. The five drugs were used either 
alone or in combination and incubated at 37°C for 30 minutes with 2 ml samples of whole 
blood obtained from normal volunteers. After labelling with Tc-99m, the radiochemical purity 
of each sample was determined. The results showed a mean LE of 97.79% for the control 
group and LE of more than 98% for each drug individually with a value of 98.87% as 
labelling efficiency for all drugs combined. From their statistical analysis of the labelling 
efficiencies obtained, there were a slight difference in values from samples containing 
antineoplastic medications and the samples containing the doxorubicin metabolites compared 
to the control. However from a clinical point of view, this difference may not be relevant.  
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One limitation of Spicer’s studies was the use of only a small number of samples. The largest 
part of information from Spicer’s study [7] and Pauwel’s work [79] was obtained from blood 
samples incubated with medication, not from patients being treated with the medicines. This 
would not represent the true situation of patients, although the concentration of medication 
added were carefully calculated to represent true concentrations in patients’ blood. In order to 
study the effect of metabolites, Spicer also obtained blood samples from 3 patients 30 minute 
post injection of doxorubicin when the product should be approximately 70% metabolised. 
Thus only a very small study was done on a single drug in a fairly realistic clinical situation.  
A more recent and accurate study performed by Lackay was carried out with 33 true patients 
on anti-tuberculosis medication with a follow up of the LE in the first phase of treatment 
(rifampicin, isonizid, pyrazinamide, ethambutol) as well as in the second phase of the 
treatment (only rifampicin and isoniazid) of the same patients. The patients’ blood samples 
taken before the commencement of treatment served as their own controls. The investigation 
was extended to examine many other factors in order to elucidate the influence of possible 
confounding factors on the results. All the labellings were performed by the same operator, 
the time elapsed after each blood sample was taken until labelling started as well as the age of 
the sodium hypochlorite used during the labelling and the age of RBCs labelling kit was 
considered. This study showed no significant effect of anti-tuberculosis treatment on in vitro 
red cell labelling [45]. 
 
The current study of the effects of malaria parasites and quinine is similar to Lackay’s work in 
the selection of actual patients with the disease treated with typical dosage regimens. Exactly 
such patients could present to Nuclear Medicine clinics in sub-Saharan Africa. The blood 
samples should show the effect of the intact drug and its metabolites.  
All the labelling throughout the current study were performed by the same operator in order to 
avoid possible operator dependant variations like more complete removal of supernatant from 
one labelling to another. All blood samples were labelled within a three month period, using 
the same lots of RBC kits and reagents. Thus confounding factors which could influence LE 
were avoided as far as possible. 
A limitation of the current study is that three different groups of people were used to represent 
the different clinical situations, i.e. without malaria, with malaria and with the disease and 
undergoing treatment. Paired testing of different influences on the same patient’s blood could 
thus not be tested, as was done in Lackay’s study of tuberculosis treatment [45]. Lastly it 
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could be argued that the fact that our control group was from a population in a malaria 
endemic area may have influenced results. A study with a control group made of people from 




The aim of this study was to determine whether or not the presence of Plasmodium 
falciparum in red blood cells and the action of the anti-malarial drug quinine on erythrocytes 
could affect labelling of red blood cells with technetium-99m. Our results show no significant 
difference in labelling efficiencies in patients without malaria, with malaria, and with malaria 
on quinine therapy.  
The presence of malaria parasites or quinine in patients’ blood should not affect Nuclear 
Medicine investigations when blood is labelled using an in vitro red blood cell labelling kit.  
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ADDENDUM 
Table A1: Table of patient age in each group 
Current effect: F(2, 87)=.69719, p=.50074. Effective hypothesis decomposition 







Control 32.66 1.845612 28.99831 36.33502 30 
M+ 30.06 1.845612 26.39831 33.73502 30 
Mm 29.93 1.845612 26.26498 33.60169 30 
 
 
Table A2: Distribution of patients in sex in each group 
Observed Frequencies  
Sex Group M+ Group M-
(control) 
Group Mm Row Totals 
M 15 14 14 43 
F 15 16 16 47 
Totals 30 30 30 90 
 
 
Table A3: Control group descriptive Statistics of %RBC with more details 






30 98.19500 97.31880 99.07120 98.96500 2.346495 








88.71000 99.81000 97.97000 99.46000 94.75500 99.71000 
 
 
Table A4: Group M+ descriptive Statistics of %RBC with more details 






30 98.57900 97.60411 99.55389 99.17500 2.610795 








85.80000 99.88000 98.93000 99.62000 97.60000 99.78000 
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Table A5: Group Mm descriptive Statistics of %RBC with more details 






30 98.62467 98.20056 99.04877 98.99500 1.135781 








94.53000 99.92000 98.11000 99.44000 97.17000 99.60000 
 
 
Table A6: All groups descriptive Statistics of %RBC with more details 






90 98.46622 98.02325 98.90919 99.10500 2.114949 








85.80000 99.92000 98.33000 99.48000 97.04500 99.71000 
 




1) Sampson CB. Complications and difficulties in radiolabelling blood cells: A review. 
Nuclear Medicine Communications 1996;17:648-658. 
 
2) Benedetto AR, Nusynowitz ML. A technique for the preparation of Tc-99m red blood cells 
for evaluation of gastrointestinal haemorrhage. Clinical Nuclear Medicine 1983;8(4):160-162. 
 
3) Schmidtchen M, Reichelt HG. The place of nuclear medicine procedures in clarifying the 
state of gastrointestinal bleeding radionuclide monitoring. Röntgen-Blätter 1990;43(6):251-
255. 
 
4) Mariani G, Pauwels EK, Al Sharif A, Marchis, Boni G, Barreca M et al. Radionuclide 
evaluation of the lower gastro intestinal tract. Journal of Nuclear Medicine 2008;49(5):776-
787. 
 
5) Howarth DM. The Role of Nuclear Medicine in the Detection of Acute Gastrointestinal 
Bleeding. Seminars in Nuclear Medicine 2006;36(2):133-146. 
 
6) Gonzalez CE, Fig LM, Cano M, Gross MO, Shapiro B. Technetium-99m red blood cell 
scintigraphy in the localization of nonenteric hemorrhage. Journal of Nuclear Medicine 
1994;35(8):1333-1337. 
 
7) Spicer JA, Hladik WB, Mulberry WE. The Effects of selected Antineoplastic Agents on the 
labelling of Erythrocytes with Technetium-99m using the UltraTag® RBC kit. Journal of 
Nuclear Medicine Technology 1999;27:132-135. 
 
8) Center for Disease Control and Prevention. Malaria [online] August 19 2011 [access 2011 
September 05]; Available: http//www.cdc.gov/malaria/disease. 
 
9) Pettersson F, Vogt AM, Jonsson C, Mok BW, Shamaei-Tousi A et al. Whole-Body 
Imaging of Sequestration of Plasmodium falciparum in the Rat. Infection and Immunity 
2005;73(11):7736-7746. 
 
Stellenbosch University  http://scholar.sun.ac.za
 32
10) Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW. The limits 
and intensity of Plasmodium falciparum transmission: implications for malaria control and 
elimination worldwide. PLOS Medicine 2008;5(2):38. 
 
11) Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of 
the malaria burden. The American Journal of Tropical Medicine and Hygiene 2001;64:1–11. 
 
12) Fontaine A, Bourdon S, Belghazi M, Pophillat M, Fourquet P, Granjeaud S, et al. 
Plasmodium falciparum infection-induced changes in erythrocyte membrane proteins. 
Parasitology Research [online] 09 July 2011 [access 2011, August 30]; available: 
http://www.springerlink.com/content/v6361q14hkh00124/fulltext.pdf. 
 
13) Weissbuch I, Leiserowitz L. Interplay Between Malaria, Crystalline Haemozoin 
Formation, and Antimalarial Drugs Action and Design. Chemical Reviews 2008;108:4899-
4914. 
 
14) Kim C, Wilson E, Derisi L. Improved methods for magnetic purification of Malaria 
parasites and haemozoin. Malaria Journal 2010;9:17. 
 
15) Bernard J, Lévy JP, Varet B, Clauvel JP, Rain J-D, Sultan Y. Abrégé d’Hématologie. 
Masson 1981;pp49-51. 
 
16) Weatherall DJ, Dingham JGG, Warell DA. Textbook of Medicine. 2nd edition Oxford 
1988;pp474-484. 
 
17) Abdelrahim II, Adam I, Elghazali G, Gustafsson LL, Elbashir MI, Mirghani RA. 
Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with 
uncomplicated Plasmodium falciparum malaria. Journal of Clinical Pharmacy and 
Therapeutics 2007;32:15-19. 
 
18) Le Jouan M, Jullien V, Tetanye E, Tran A, Rey E, Tréluyer JM et al. Quinine 
pharmacokinetics and pharmacodynamics in Children with Malaria Caused by Plasmodium 
falciparum. Antimicrobial Agents and Chemotherapy 2005;l49(9):3658-3662. 
 
Stellenbosch University  http://scholar.sun.ac.za
 33
19) Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. Defining the role of PfCRT 
in Plasmodium falciparum chloroquine resistance. Molecular Microbiology 2005;56:323–333. 
 
20) Uhlemann A, Yuthavong Y, Fidock DA. Mechanisms of Antimalarial Drug Action and 
Resistance. In Sherman IW, editor. Molecular Approaches to Malaria. Washington: ASM 
Press 2005;pp429–461. 
 
21) Thompson AJ, Lochner M, Lummis SCR. The antimalarial drugs quinine, chloroquine 
and mefloquine are antagonists at 5-HT3 receptors. British Journal of Pharmacology 
2007;151,666–677. 
 
22) Ross MH, Wojciech P. Histology, a Text and Atlas with correlated cell and molecular 
biology. 5th edition Philadelphia: Lippincott Williams & Wilkins 2006;pp249-251. 
 
23) Waugh A, Grant A. Ross and Willson Anatomy and Physiology in Health and Illness. 10th 
edition Philadelphia: Elsevier limited 2006;pp59-61. 
 
24) Fisher J, Wolf R, Leon A. Technetium-99m as a label for erythrocytes. Journal of Nuclear 
Medicine 1967;8:229-232. 
 
25) Larson SM, Hamilton GW, Richards P, Ritchie JL. Kit-Labelled Technetium-99m Red 
Blood Cells (Tc-99m-RBC’s) for Clinical Cardiac Chamber Imaging. European Journal of 
Nuclear Medicine 1978;3:227-231. 
 
26) Pasquier J, Laforte C, Roux F, Leonetti J., Bardy A, Hegesippe M, Bernard PJ. The Use 
of High Activity 99mTc labeled Red Blood Cells for Ventricular Contraction Measurement 
with an Unsophisticated Cardiac Synchronizer Linked to a Gamma Camera. European Journal 
of Nuclear Medicine 1977;2:13-18. 
 
27) Linderkamp O, Betke K, Fendel H, Klemm J, Lorenzen K, Riegel KP. Tc-99m-labeled 
red blood cells for the measurement of red cell mass in newborn infants: Concise 
communication. Journal of Nuclear Medicine 1980;21(7):637-640. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 34
28) Mock BH, Wellman HN. Stoichiometric Tc-99m RBC labeling using Stable Kit Solutions 
of Stannous Chloride and EDTA: concise communication. Journal of Nuclear Medicine 
1984;25:881-886. 
 
29) Patrick ST, Glowniak JV, Turner FE, Robbins MS, Wolfangel RG. Comparison of In 
Vitro RBC Labeling with the UltraTag® RBC Kit Versus In Vivo labeling. Journal of Nuclear 
Medicine 1991;32:242-244. 
 
30) Bauer R, Haluszczynski I, Langhammer H, Bachmann W. In vivo/in vitro Labeling Red 
Blood Cells with 99mTc. European Journal of Nuclear Medicine 1983;8:218-222. 
 
31) Nappi A, Cuocolo A, Lazzetta N, Aldo FL, Marotta T, Pace L, et al. Ambulatory 
monitoring of left ventricular function in patients with Parkinson’s disease and postural 
hypotension. European Journal of Nuclear Medicine 1994;21:1312-1317. 
 
32) Inoue Y, Wakita S, Yoshikawa K, Kaji N, Yoshioka N, Ohtake T, et al. Evaluation of 
flow characteristics of soft-tissue vascular malformations using technetium-99m labelled red 
blood cells. European Journal of Nuclear Medicine 1996;26:367-372. 
 
33) Schillaci O, Spanu A, Tagliabue L, Filippi L, Danieli R, Palumbo B, et al. SPECT/CT 
with a hybrid imaging system in the study of lower gastrointestinal bleeding with technetium-
99m red blood cells. Quarterly Journal of Nuclear Medicine 2009;53:281-289. 
 
34) Srivastava SC, Chervu LR. Radionuclide-Labeled Red Blood Cells: Current Status and 
Future Prospects. Seminars in Nuclear Medicine 1984;14(2):68-82. 
 
35) Eckelman w, Richards P, Hauser W, Atkin H. Technetium labelled red blood cells. 
Journal of Nuclear Medicine 1979;20:22-24. 
 
36) Neumann P, Schicha H, Schürnbrand P, Bähre M, Emrich D. Visualizing Cardiac Blood 
Pool: Comparison of Three Labeling methods. European Journal of Nuclear Medicine 
1983;8:463-466. 
 
Stellenbosch University  http://scholar.sun.ac.za
 35
37) Creutzig H. Labeling of red blood cells. European Journal of Nuclear Medicine 
1984;9:294. 
 
38) Early PJ, Sodee DB. Principles and practice of Nuclear Medicine. 2nd edition New York: 
Mosby 1995;pp109-110. 
 
39) Hamilton RG, Anderson PO. A Comparative Evaluation of Techniques for Rapid and 
Efficient in Vivo Labeling of Red Cells with [99mTc] Pertechnetate. Journal of Nuclear 
Medicine 1977;18:1008-1011. 
 
40) Sampson C.B. Textbook of Radiopharmacy Theory and Practice. Volume 3 New York: 
Gordon and Breach Publishers 1990;pp210-216. 
 
41) Kelbaek H, Bülow K, Aldershvile J, Mogelvang J, Nielsen SL. A new 99mTc red blood 
cell labeling procedure for cardiac blood pool imaging: clinical results. European Journal of 
Nuclear Medicine 1989;15:333-335. 
 
42) Kelbaek H, Gjorup T, Fogh J. In vivo stability of in vitro labelled 99Tcm-red blood cells 
for radionuclide determination of left ventricular ejection fractions and volumes. Nuclear 
Medicine Communications 1986;7:541-547. 
 
43) UltraTag® RBC package insert. St. Louis, MO; Mallinckrodt. Revised 4/2005. 
 
44) Le Roux JS. Die produksie en kwaliteitskontrole van Tegnesium-99m kitsstelle met 
spesiale verwysing na ‘n kitsstel vir rooiselmerking. MSc thesis Stellenbosch University 
1991. 
 
45) Lackay CL. Evaluation of the labelling and binding efficiency of Tc-99m to red blood 
cells of patients who are being exposed to a cocktail of anti-tuberculosis drugs. Cape 
Peninsula University of Technology Theses & Dissertations. Paper 159 2010 
http://dk.cput.ac.za/td_cput/159, accessed 30 July2011. 
 
46) Diré G, Lima E, Mattos D, Oliveira MB, Pereira MJ, Moreno S, Freitas R, Gomes ML, et 
al. Effect of chayotte (Sechium edule) extract on the biodistribution of technetium-99m and 
Stellenbosch University  http://scholar.sun.ac.za
 36
on the morphometry of red blood cells. Journal of Labelled Compound Radiopharmaceuticals 
2001;44:648-650. 
 
47) Nigri F, Oliveira MB, Bernardo-Filho M. Assessment of the Effect of antiseizure drugs on 
the labelling process of red blood cells and plasma proteins with technetium-99m. Cellular 
and Molecular Biology 2002;48(7):793-801. 
 
48) Capriles PVSZ, Dias APM, Costa TEMM, Oliveira MBN, Faria MVC, Moura EG, et al. 
Effect of eggplant (Solanum melongena) extract on the in vitro labelling of blood elements 
with technetium-99m and on the biodistribution of sodium pertechnetate in rats. Cellular and 
Molecular Biology 2002;48:771-776. 
 
49) Gomes ML, Mattos DM, Freitas RS, Diré GF, Lima EAC, Souza SMS, et al. Evaluation 
of the effect of mitomycin-C on the bioavailability of technetium-99m-labelled sodium 
pyrophosohate in mice. Cellular and Molecular Biology 2002;48:757-759.  
 
50) Moreno SRF, Freitas R, Diré G, Farah M, Lima E, Lima-Filho GL et al. Evaluation of the 
Effect of a Gingko biloba Extract on the Biodistribution of Sodium Pertechnetate in Rats and 
on the Morphology of Red Blood Cells. Technetium, Rhenium and Other Metals in Chemistry 
and Nuclear Medicine. SG Editoriali, Padova 2002;6:531-533. 
 
51) De Oliveira JF, Braga ACS, Ávila ASR, Gutfilen B, Bernardo-Filho M. Effect of Thuya 
occidentalis on the labeling of red blood cells and plasma proteins with technetium-99m. Yale 
Journal of Biology and Medicine 1997;69:489-494. 
 
52) Vidal MV, Gutfilen B, Fonseca LMB, Bernardo-Filho M. Influence of tobacco on the 
labelling of red blood cells and plasma proteins with technetium-99m. Journal of 
Experimental and Clinical Cancer Research 1998;17:1-16. 
 
53) Braga AC, Oliveira MB, Feliciano GD, Reiniger IW, Oliveira JF, Silva CR, et al. The 
effect of drugs on the labeling of blood elements with technetium-99m. Current 
Pharmaceutical Design 2000;6(11):1179-1191. 
 
Stellenbosch University  http://scholar.sun.ac.za
 37
54) De Oliveira JF, Braga AC, Ávila AS, Caldeira de Araujo A, Cardoso VN, Bezerra RJ, et 
al. Assessment of the effect of Maytenus ilicifolia (Espinheira-santa) extract on the labeling of 
red blood cells and plasma proteins with technetium-99m. Journal of Ethnopharmacology 
2000;72(1-2):179-184. 
 
55) Filho SD, Ribeiro CK, Diré GF, Lima E, Pereira M, Bernardo-Filho M. Morphological 
Alterations on Red Blood Cells Labeled with Technetium-99m: the Effect of Mentha crispa L. 
(Hortelã) and Piper methysticum (Kava Kava) Extracts. Technetium, Rhenium and Other 
Metals in Chemistry and Nuclear Medicine. SG Editoriali Padova 2002;6:503-505. 
 
56) De Oliveira JF, Ávila AS, Braga AC, De Oliveira MB, Boasquevisque EM, Jales RL et al. 
Effect of extract of medicinal plants on the labeling of blood elements with Technetium- 99m 
and on the morphology of red blood cells: a study with Paullinia cupana. Fitoterapia 
2002;73(4):305-312. 
 
57) Leitl GP, Drew HM, Kelly ME,  Alderson PO. Interference with Tc-99m labeling of red 
blood cells (RBC’s) by RBC antibodies [abstract]. Journal of Nuclear Medicine 
1980;21(6):44. 
 
58) De Paoli S, Giani TS, Presta GA, Pereira MO, Da Fonseca AD, Brandao-Neto J et al. 
Effects of Clove (Caryphyllus aromaticus L) on the labeling of blood constituents with 
technetium-99m and on morphology of red blood cells. Brazilian Archives of Biology and 
Technology 2007;50:175-182. 
 
59) Sampson CB. Interference of patient medication in the radiolabeling of white blood cells: 
An update. Nuclear Medicine Communications 1998;19:529-535. 
 
60) Sampson C.B. Textbook of Radiopharmacy Theory and Practice. 2nd enlarged edition 
Volume 3 New York: Gordon and Breach Publishers 1994;pp222-223. 
 
61) Sampson CB. Adverse reactions and Drugs interactions with radiopharmaceuticals. Drug 
Safety. 1993;8(3):280-294. 
 
Stellenbosch University  http://scholar.sun.ac.za
 38
62) Gleue AD, Spicer JA, Preston DF. Effect of Cyclosporine on Technetium-99m Red blood 
cell labelling using UltraTag® RBC kit. Journal of Nuclear Medicine Technolology 
1995;23(1):22. 
 
63) Moreno SR, Carvalho JJ, Nascimento AL, Pereira M, Caldas L QA, Bernardo-Filho M. 
Effects of Nectandra Membranacea Extract on Labeling of Blood Constituents with 
Technetium-99m and on the Morphology of Red Blood Cells. World Academy of Science 
Engineering and Technology 2011;75:753-757. 
 
64) Diré GF, Fernandes JFO, Gomes ML, Albuquerque AC, Camacho MEO, Lima RC, et al. 
Comprehensive Analysis of the Biological Effects Related to a Natural Extract Processed 
from Bark of Chayote (Sechium Edule). Global Veterinaria 2010;4(3):225-229. 
 
65) Diré GF, Fernandes JF, Gomes ML, Albuquerque AC, Almeida ST, Ferreira MJ. et al. 
Analysis of the biological effects of edule fruit extract: morphological and radiobiological 
study. Life Science Journal 2009;6(3):80-82. 
 
66) Kakali D, Susmita C, Mridula M. Assessment of the effect of Bacopa monnieri (L) wettst 
extract on the labeling of blood elements with technetium-99m and on the morphology of red 
blood cells. Brazilian Journal of Pharmacognosy 2009;19(3):664-671. 
 
67) Aquino TM, Amorim Elba LC, Diré GF, Lima EAC, Gomes ML, Lima CSA, et al. 
Influence of biflorin on the labelling of red blood cells, plasma protein, cell protein, and 
lymphocytes with technetium-99m: in vitro study. Brazilian Journal of Pharmacognosy 
2007;17(2):181-185. 
 
68) Adalet I, Cantez S. Poor-quality red blood cell labelling with technetium-99m: case report 
and review of the literature. European Journal of Nuclear Medicine 1994;21:173-175. 
 
69) Dewanjee MK. Binding of 99mTc ion to haemoglobin. Journal of Nuclear Medicine 
1974;15:703-706. 
 
Stellenbosch University  http://scholar.sun.ac.za
 39
70) Gomes ML, Nunes de Oliveira MB, Bernardo-Filho M. Drug Interaction with 
Radiopharmaceuticals: Effect on the labeling of Red Blood Cells with Technetium-99m and 
on the Bioavailability of Radiopharmaceuticals. Brazilian Archives of Biology and 
Technology 2002;45:143-149. 
 
71) Lee HB, Wexler JP, Scharf SC, Blaufox MD. Pharmacologic Alterations in Tc99m 
binding by red blood cells: concise communication. Journal of Nuclear Medicine 
1983,24(5):397-401. 
 
72) Tatum JL, Burke TS, Hirsch JI, Miller WW, Fratkin MJ. Pitfall to Modified in Vivo 
Method of Technetium 99m Red Blood Cell Labelling. Iodinated Contrast Media. Clinical 
Nuclear Medicine 1983;8(12):585-587. 
 
73) Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals European Journal 
of Nuclear Medicine 1994;21:348-356.  
 
74) Hambye AS, Vandermeiren R, Vervaet A, Vandevivere J. Failure to label red blood cells 
adequately in daily practice using an in vivo method: methodological and clinical 
considerations. European Journal of Nuclear Medicine 1995;22(1):61-67. 
 
75) Owunwanne A, Shihab-Eldeen A. The effect of Cyclosporine-A on labelling blood cells 
with radiopharmaceuticals. Nuclear Medicine and Biology 1996;23:1019-1021. 
 
76) Abreu PRC, Almeida MC, Bernardo RM, Bernardo LC, Brito LC, Garcia EAC et al. 
Guava extract (Psidium guajava) alters the labelling of blood constituents with technetium-
99m. Journal of Zhejiang University SCIENCE B 2006;7(6):429-435. 
 
77) De Oliveira JF, Nunes de Oliveira MB, Avila AS, Braga AC, Catanho MT, Jales RL et al. 
Assessment of the effect of Fucus vesiculosus extract on the labeling of blood constituents 
with technetium-99m and histological modifications on the red blood cells. Food and 
Chemical toxicology 2003;41:15-20. 
 
Stellenbosch University  http://scholar.sun.ac.za
 40
78) Diré GF, Dias GJ, Brito LC, Soares SF, Rabelo GP, Pessoa CC et al. Effect of Chayote 
(Sechium edule) extract on the radiolabelling of blood elements in diabetic rats. Boletin 
Latinoamericano y del Caribe de Plantas Medicinales Y Aromaticas 2006;2(5)pp36-41. 
 
79) Pauwels EKJ, Feitsma RIJ, Blom J. Influence of adriamycin on red blood cell labelling; a 
pitfall in scintigraphic blood pool imaging. Nuclear Medicine Communication 1983;4:290-
295. 
 
80) Gerson B, Ballinger JR, Gulenchyn KY. Improved Modification for In Vivo Labeling of 





Stellenbosch University  http://scholar.sun.ac.za
